Nicholas Investment Partners’s Ultragenyx Pharmaceutical RARE Stock Holding History

Nicholas Investment Partners’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-229,492	Closed	-$13.7M	–	196
2022 Q2	$13.7M	Buy	+229,492	New	+$14.1M	1.29%	21
2016 Q2	–	Sell	-25,142	Closed	-$1.59M	–	326
2016 Q1	$1.59M	Sell	25,142 -4,017	-14%	-$263K	0.12%	259
2015 Q4	$3.27M	Buy	29,159 +5,677	+24%	+$568K	0.23%	185
2015 Q3	$2.26M	Buy	+23,482	New	+$2.69M	0.16%	230

Other funds holding RARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Nicholas Investment Partners's RARE Position: Q3 2022 in Review

Nicholas Investment Partners sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2022, closing a stake of 229,492 shares — an estimated $13.7M sold.

Nicholas Investment Partners first reported a position in RARE in Q3 2015 and held it in 4 quarters. The position peaked at $13.7M in Q2 2022. 233 funds tracked by Wall St. Rank hold RARE as of Q3 2022.

Nicholas Investment Partners reported no remaining Ultragenyx Pharmaceutical position as of Q3 2022 after selling out during the quarter.
Nicholas Investment Partners sold 229,492 Ultragenyx Pharmaceutical shares in Q3 2022, an estimated $13.7M.
Nicholas Investment Partners first reported a position in Ultragenyx Pharmaceutical in Q3 2015 and held it in 4 quarters.
Nicholas Investment Partners's Ultragenyx Pharmaceutical position peaked at $13.7M in Q2 2022.
233 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2022.

Based on Nicholas Investment Partners's 13F filing for Q3 2022, filed 14 Nov 2022.